Literature DB >> 321166

Levamisole and human lymphocyte surface markers.

J Wybran, A Govaerts.   

Abstract

The action of various concentrations of levamisole on normal human lymphocytes was investigated in vitro. The action of levamisole (10(-1) mg-10(-8) mg%) upon rosette formation was studied using two rosette assays with SRBC (the active and the total T-rosette tests) to quantify T cells and the EAC assay to quantify B cells. Levamisole at only 10(-3) mg% significantly increased the percentage of both active and total T cells. In sharp contrast, levamisole between 10(-2) and 10(-7) mg% significantly decreased the EAC percentage. It is concluded that levamisole promotes a better expressivity of T-cell receptor and decreases the expressivity of C3 receptor.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 321166      PMCID: PMC1540780     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  11 in total

1.  The significance of varying SRBC/lymphocyte ratio in T cell rosette formation.

Authors:  R L Chisholm; D G Tubergen
Journal:  J Immunol       Date:  1976-05       Impact factor: 5.422

2.  The active E rosette test: correlation with delayed cutaneous hypersensitivity.

Authors:  P J Felsburg; R Edelman; R H Bilman
Journal:  J Immunol       Date:  1976-04       Impact factor: 5.422

3.  Beta-adrenergic inhibition of human T lymphocyte rosettes.

Authors:  S P Galant; R A Remo
Journal:  J Immunol       Date:  1975-01       Impact factor: 5.422

4.  Effects of levamisole and imidazole on lymphocyte proliferation and cyclic nucleotide levels.

Authors:  J W Hadden; R G Coffey; E M Hadden; E Lopez-Corrales; G H Sunshine
Journal:  Cell Immunol       Date:  1975-11       Impact factor: 4.868

5.  Thymus-derived rosette-forming cells.

Authors:  J Wybran; H H Fudenberg
Journal:  N Engl J Med       Date:  1973-05-17       Impact factor: 91.245

6.  Isolation of normal T cells in chronic lymphatic leukaemia.

Authors:  J Wybran; S Chantler; H H Fudenberg
Journal:  Lancet       Date:  1973-01-20       Impact factor: 79.321

7.  Levamisole and cell-mediated immunity and serum-immunoglobulins in rheumatoid arthritis.

Authors:  H Szpilman; S Luft; D Glińska-Urban; W Fischer; M Plachecka
Journal:  Lancet       Date:  1976-07-24       Impact factor: 79.321

8.  Antigenic competition and nonspecific immunity after a rickettsial infection in mice: restoration of antibacterial immunity by phenyl-imidothiazole treatment.

Authors:  G Renoux; M Renoux
Journal:  J Immunol       Date:  1972-10       Impact factor: 5.422

9.  Effects of levamisole on spontaneous rosette-forming cells in murine spleen.

Authors:  R F van Ginckel; J Hoebeke
Journal:  Eur J Immunol       Date:  1976-04       Impact factor: 5.532

10.  Thymus-derived rosette-forming cells in various human disease states: cancer, lymphoma, bacterial and viral infections, and other diseases.

Authors:  J Wybran; H H Fudenberg
Journal:  J Clin Invest       Date:  1973-05       Impact factor: 14.808

View more
  5 in total

1.  Active E rosette formation by human lymphoblasts.

Authors:  G Semenzato; G Amadori; P Sarasin; G Gasparotto
Journal:  Immunology       Date:  1978-04       Impact factor: 7.397

2.  The effect of levamisole on E-rosette formation by trypsinized lymphocytes.

Authors:  R Lomnitzer; A R Rabson
Journal:  Clin Exp Immunol       Date:  1978-09       Impact factor: 4.330

3.  New approaches to immunotherapy: thymomimetic drugs.

Authors:  S Specter; J W Hadden
Journal:  Springer Semin Immunopathol       Date:  1985

4.  Levamisole and HBsAg positive chronic persistent hepatitis.

Authors:  M Masi; P Paolucci; G Timoncini; M P Fantini; G Leggieri; F Chiodo; C Franceschi
Journal:  Arch Dis Child       Date:  1978-09       Impact factor: 3.791

5.  In vivo effect of levamisole on cellular and humoral immunity in normal chickens.

Authors:  E Soppi; O Lassila; M K Viljanen; O P Lehtonen; J Eskola
Journal:  Clin Exp Immunol       Date:  1979-12       Impact factor: 4.330

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.